Celltech appoints new US president
The Celltech group as appointed Daniel Greenleaf as president, US operations based at its Rochester, NY, facility.
The Celltech group as appointed Daniel Greenleaf as president, US operations based at its Rochester, NY, facility.
Greenleaf will report to Ingelise Saunders, ceo Celltech Pharmaceuticals, and will lead the US organisation in the commercialisation of pipeline products including, CDP870, and in driving the growth of the existing portfolio including Celltech's cough/cold products, Tussionex and Delsym, and Dipentum, a treatment for ulcerative colitis.
Greenleaf has held a number of senior positions in the biotech and pharmaceutical industries, latterly as senior vice president operations at Nabi Biopharmaceuticals, a producer of autoimmune and infectious disease products. In this position he was responsible for all US domestic and international sales, marketing, manufacturing, managed care and business development activities.
Prior to this, he spent ten years at Schering-Plough Corporation, starting as a sales representative before taking on a number of increasingly senior roles in managed care, marketing and strategic ventures. This included a period as vice president, marketing and sales for one of Schering-Plough's subsidiary companies.
Ingelise Saunders, ceo Celltech Pharmaceuticals, commented: 'I am looking forward to welcoming Daniel to Celltech. His extensive experience in sales and in managed care marketing in addition to his strategic planning, business development and leadership skills make him the ideal candidate to support us in our goal of becoming a global biotechnology leader.'